TG Therapeutics, Inc. (TGTX)
NASDAQ: TGTX · IEX Real-Time Price · USD
21.00
-0.23 (-1.08%)
At close: Jul 19, 2024, 4:00 PM
21.24
+0.24 (1.14%)
Pre-market: Jul 22, 2024, 7:35 AM EDT
TG Therapeutics Revenue
TG Therapeutics had revenue of $289.33M in the twelve months ending March 31, 2024, with 3,275.73% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $63.47M with 713.46% year-over-year growth. In the year 2023, TG Therapeutics had annual revenue of $233.66M with 8,290.02% growth.
Revenue (ttm)
$289.33M
Revenue Growth
+3,275.73%
P/S Ratio
11.22
Revenue / Employee
$1,095,962
Employees
264
Market Cap
3.25B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 233.66M | 230.88M | 8,290.02% |
Dec 31, 2022 | 2.79M | -3.90M | -58.36% |
Dec 31, 2021 | 6.69M | 6.54M | 4,300.66% |
Dec 31, 2020 | 152.00K | - | - |
Dec 31, 2019 | 152.00K | - | - |
Dec 31, 2018 | 152.00K | - | - |
Dec 31, 2017 | 152.00K | - | - |
Dec 31, 2016 | 152.00K | - | - |
Dec 31, 2015 | 152.00K | - | - |
Dec 31, 2014 | 152.00K | -381.00 | -0.25% |
Dec 31, 2013 | 152.38K | 133.33K | 699.98% |
Dec 31, 2012 | 19.05K | - | - |
Dec 31, 2011 | 0 | - | - |
Dec 31, 2010 | 0 | - | - |
Dec 31, 2009 | 0 | - | - |
Dec 31, 2008 | 0 | - | - |
Dec 31, 2007 | 0 | - | - |
Dec 31, 2006 | 0 | - | - |
Dec 31, 2005 | 0 | - | - |
Dec 31, 2004 | 0 | - | - |
Dec 31, 2003 | 0 | - | - |
Aug 1, 2002 | 0 | - | - |
Dec 31, 2001 | 2.71M | -2.65M | -49.39% |
Dec 31, 2000 | 5.36M | 4.20M | 362.15% |
Dec 31, 1999 | 1.16M | -1.34M | -53.62% |
Dec 31, 1998 | 2.50M | 2.50M | 109,165.73% |
Dec 31, 1997 | 2.29K | -95.36K | -97.66% |
Dec 31, 1996 | 97.64K | - | - |
Dec 31, 1995 | 0 | - | - |
Dec 31, 1994 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Amedisys | 2.25B |
HUTCHMED (China) | 838.00M |
GoodRx Holdings | 764.16M |
Inari Medical | 520.66M |
Axonics | 387.14M |
PROCEPT BioRobotics | 156.33M |
Arcellx | 131.66M |
IDEAYA Biosciences | 15.50M |
TGTX News
- 6 weeks ago - TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - GlobeNewsWire
- 7 weeks ago - TG Therapeutics to Participate in the Jefferies Global Healthcare Conference - GlobeNewsWire
- 7 weeks ago - TG Therapeutics Announces Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting - GlobeNewsWire
- 7 weeks ago - TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting - GlobeNewsWire
- 2 months ago - TG Therapeutics stock just rallied 30%: what happened? - Invezz
- 2 months ago - TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 2 months ago - TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update - GlobeNewsWire
- 3 months ago - TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting - GlobeNewsWire